Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/s41598-017-01571-0.pdf
Reference52 articles.
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA: a cancer journal for clinicians 67, 7–30, doi: 10.3322/caac.21387 (2017).
2. Hamilton, G. & Rath, B. Smoking, inflammation and small cell lung cancer: recent developments. Wiener medizinische Wochenschrift 165, 379–386, doi: 10.1007/s10354-015-0381-6 (2015).
3. Kahnert, K., Kauffmann-Guerrero, D. & Huber, R. M. SCLC-State of the Art and What Does the Future Have in Store? Clinical lung cancer, 10.1016/j.cllc.2016.05.014 (2016).
4. Dores, G. M., Qubaiah, O., Mody, A., Ghabach, B. & Devesa, S. S. A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992–2010. BMC cancer 15, 185, doi: 10.1186/s12885-015-1188-y (2015).
5. Paglialunga, L., Salih, Z., Ricciuti, B. & Califano, R. Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? ESMO open 1, e000022, doi: 10.1136/esmoopen-2015-000022 (2016).
Cited by 132 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer;Investigational New Drugs;2024-02-01
2. Prognostic implications of neutrophil‐to‐lymphocyte ratio in patients with extensive‐stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real‐world study;Thoracic Cancer;2024-01-31
3. Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review;International Cancer Conference Journal;2023-12-21
4. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline;Journal of Clinical Oncology;2023-12-10
5. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis;BMC Cancer;2023-12-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3